Search Results - "Dalal, Rahul S"

Excipient Exception: A Complication of Infliximab and Vedolizumab Infusions for Ulcerative Colitis by Dalal, Rahul S., Goksel, Behiye, Hamilton, Matthew J.

Get full text

Activity of axial spondyloarthritis after one year of anti-tumor necrosis factor therapy among patients with inflammatory bowel diseases by Dalal, Rahul S., Ermann, Joerg, Carlin, Alexander, Mitri, Jennifer, Allegretti, Jessica R.

“…The disease activity of axSpA after initiating anti-TNF agents for inflammatory bowel diseases (IBD) is poorly understood. We sought to examine the disease…”
Get full text

Tofacitinib for the Treatment of Pouch-Related Disorders: A Case Series by Dalal, Rahul S, Bains, Kanwal, Marcus, Jenna, McClure, Emma L, Allegretti, Jessica R

“…Lay Summary In this case series, 6 patients with chronic pouchitis (n = 3), cuffitis (n = 2), or Crohn’s-like disease of the pouch (n = 1) were treated with…”
Get full text

Inpatient Gastroenterology Workups Prior to Transesophageal Echocardiogram: Is It Time for a Change of Heart? by DALAL, RAHUL S., RUBIN, DEBORAH C.

Get full text

Effects of Alcohol on Postoperative Adhesion Formation in Ischemic Myocardium and Pericardium by Elmadhun, Nassrene Y., MD, Sabe, Ashraf A., MD, Lassaletta, Antonio D., MD, Dalal, Rahul S., MD, Sellke, Frank W., MD

“…Background Postoperative formation of adhesions increases risk of complications during cardiac reoperations. We previously demonstrated that swine supplemented…”
Get full text

Limiting Opioid Use for Patients Who Are Hospitalized for Inflammatory Bowel Disease Exacerbations by Dalal, Rahul S

Get full text

Resveratrol regulates autophagy signaling in chronically ischemic myocardium by Sabe, Ashraf A., MD, Elmadhun, Nassrene Y., MD, Dalal, Rahul S., BS, Robich, Michael P., MD, Sellke, Frank W., MD

“…Objective Autophagy is a cellular process by which damaged components are removed. Although autophagy can result in cell death, when optimally regulated, it…”
Get full text

Author Spotlight: Rahul S. Dalal by Dalal, Rahul S.

Get full text

Preoperative gene expression may be associated with neurocognitive decline after cardiopulmonary bypass by Sabe, Ashraf A., MD, Dalal, Rahul S., BS, Chu, Louis M., MD, Elmadhun, Nassrene Y., MD, Ramlawi, Basel, MD, Bianchi, Cesario, MD, PhD, Sellke, Frank W., MD

“…Objective Despite advances in surgical techniques, neurocognitive decline after cardiopulmonary bypass remains a common and serious complication. We have…”
Get full text

Real-World Comparison of Tofacitinib vs Ustekinumab Among Bio-Exposed Patients With Ulcerative Colitis: A Propensity Score Analysis by Dalal, Rahul S, Mitri, Jennifer, Goodrick, Hannah, Allegretti, Jessica R

Get full text

COVID-19 Vaccination Intent and Perceptions Among Patients With Inflammatory Bowel Diseases by Dalal, Rahul S., McClure, Emma, Marcus, Jenna, Winter, Rachel W., Hamilton, Matthew J., Allegretti, Jessica R.

“…Patients with inflammatory bowel disease (IBD) develop coronavirus disease 2019 (COVID-19) at similar rates as the general population, and there was initial…”
Get full text

Investigating the effects of resveratrol on chronically ischemic myocardium in a swine model of metabolic syndrome: a proteomics analysis by Sabe, Ashraf A, Sadek, Ahmed A, Elmadhun, Nassrene Y, Dalal, Rahul S, Robich, Michael P, Bianchi, Cesario, Sellke, Frank W

“…Resveratrol has been shown to improve cardiac perfusion and ventricular function after chronic ischemic injury. Using proteomic analysis, we sought to…”
Get more information

Reply: In Severe Inflammatory Bowel Disease, the Onset of Effectiveness of Biologics and Small Molecules Depends More on the Medication Than on the Diagnosis by Dalal, Rahul S, Allegretti, Jessica R

Get full text

Predictors and Outcomes of Ustekinumab Dose Intensification in Ulcerative Colitis: A Multicenter Cohort Study by Dalal, Rahul S., Esckilsen, Scott, Barnes, Edward L., Pruce, Jordan C., Marcus, Jenna, Allegretti, Jessica R.

“…Ustekinumab has been shown to be effective for the treatment of ulcerative colitis (UC); however, >40% of patients have suboptimal clinical response after…”
Get full text

Reply: Tofacitinib in Ulcerative Colitis: Beyond Biologics? by Dalal, Rahul S, Allegretti, Jessica R

Get full text

Predictors of Ustekinumab Failure in Crohn’s Disease After Dose Intensification by Dalal, Rahul S, Njie, Cheikh, Marcus, Jenna, Gupta, Sanchit, Allegretti, Jessica R

“…Abstract Background Many patients with Crohn’s disease (CD) who lose response to the standard ustekinumab dose interval of every 8 weeks (q8w) undergo dose…”
Get full text

Risk of Gastrointestinal Infections After Initiating Vedolizumab and Anti-TNFα Agents for Ulcerative Colitis by Dalal, Rahul S., Mitri, Jennifer, Goodrick, Hannah, Allegretti, Jessica R.

“…Characterize and compare the risk of Clostridioides difficile infection (CDI) and cytomegalovirus colitis (CMVC) after initiation of vedolizumab or anti-tumor…”
Get full text

Does resveratrol improve insulin signaling in chronically ischemic myocardium? by Sabe, Ashraf A., MD, Elmadhun, Nassrene Y., MD, Robich, Michael P., MD, Dalal, Rahul S., BS, Sellke, Frank W., MD

“…Abstract Background Resveratrol is a naturally occurring polyphenol believed to be cardioprotective. We previously demonstrated that resveratrol improves…”
Get full text

Long-Term Outcomes After Ustekinumab Dose Intensification for Inflammatory Bowel Diseases by Dalal, Rahul S, Pruce, Jordan C, Allegretti, Jessica R

“…Lay Summary In this retrospective cohort study, we demonstrated that dose intensification of ustekinumab to every 4 or every 6 weeks was effective in both…”
Get full text

Diagnosis and management of Clostridioides difficile infection in patients with inflammatory bowel disease by Dalal, Rahul S., Allegretti, Jessica R.

“…Clostridioides difficile infection (CDI) may complicate the course of ulcerative colitis and Crohn's disease. The clinical presentation of CDI in this…”
Get full text